Altanova is establishing a Swissmedic-aligned sourcing and release framework under EU GMP standards. Swiss GMP inspections are recognised by the European Union under the EU–Switzerland Mutual Recognition Agreement. Batch release will be performed through qualified Swiss and EU GMP partners under Altanova's quality architecture.
Citation: Art. 5–7 AMBV · EU-CH MRA
The manufacture, distribution and dispensing of controlled substances in Switzerland is governed by the Federal Act on Narcotic Drugs and Psychotropic Substances (BetmG) and the Narcotics Control Ordinance (BetmKV). Where a therapeutic franchise handles controlled products, that framework confines all activity to the regulated medical channel; Altanova's standing policy is strict separation from any non-medical market.
Citation: Art. 4 BetmG · BetmKV
Healthcare professionals and patients are asked to report any suspected adverse reactions through the routes described on our Safety reporting page, or directly to Swissmedic through the ElViS electronic vigilance system. Social-media channels are not a forum for adverse-event reporting.
Citation: Art. 59 HMG · Swissmedic ElViS
Active pharmaceutical ingredients and excipients are sourced from qualified suppliers and assessed against defined product and quality requirements. For botanical materials, supplier qualification also considers applicable cultivation and collection standards.
Testing is designed around European Pharmacopoeia methods, with Swiss technical release performed through qualified partners. The full testing panel, including franchise-specific requirements, is defined per product specification.
Distribution is designed for temperature-controlled, tamper-evident handling with full chain-of-custody documentation, through wholesalers operating under EU-GDP and national narcotics authorisations.
Healthcare professionals and patients can report suspected adverse reactions through Altanova's dedicated reporting channel.